Molecular Partners grants Allergan exclusive rights to MP0260 to treat wet age-related macular degeneration (AMD) and partners with Allergen to develop DARPins for serious ophthalmic diseases

Molecular Partners AG

Switzerland / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!; This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Allergan Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!; This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced